CA1163517A - Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid - Google Patents
Method and apparatus for on-line filtration removal of macromolecules from a physiological fluidInfo
- Publication number
- CA1163517A CA1163517A CA000377362A CA377362A CA1163517A CA 1163517 A CA1163517 A CA 1163517A CA 000377362 A CA000377362 A CA 000377362A CA 377362 A CA377362 A CA 377362A CA 1163517 A CA1163517 A CA 1163517A
- Authority
- CA
- Canada
- Prior art keywords
- plasma
- stream
- macromolecules
- solution
- plasma stream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 63
- 238000001914 filtration Methods 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 31
- 239000012530 fluid Substances 0.000 title claims description 26
- 239000012528 membrane Substances 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 239000008280 blood Substances 0.000 claims abstract description 24
- 238000000926 separation method Methods 0.000 claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 210000002381 plasma Anatomy 0.000 claims description 151
- 238000001816 cooling Methods 0.000 claims description 25
- 210000004379 membrane Anatomy 0.000 claims description 21
- 230000001413 cellular effect Effects 0.000 claims description 20
- 238000004891 communication Methods 0.000 claims description 19
- 230000006854 communication Effects 0.000 claims description 19
- 238000007710 freezing Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 8
- 230000036760 body temperature Effects 0.000 claims description 5
- 239000008139 complexing agent Substances 0.000 claims description 4
- 210000003567 ascitic fluid Anatomy 0.000 claims description 3
- 210000004880 lymph fluid Anatomy 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 229910052729 chemical element Inorganic materials 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 36
- 108010088751 Albumins Proteins 0.000 description 14
- 102000009027 Albumins Human genes 0.000 description 14
- 238000002616 plasmapheresis Methods 0.000 description 11
- 108010091326 Cryoglobulins Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101150039033 Eci2 gene Proteins 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000531897 Loma Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 206010063676 Rhesus incompatibility Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- -1 nonionic or ionic Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000426017A CA1170138A (en) | 1980-05-29 | 1983-04-15 | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| CA000436234A CA1176574A (en) | 1980-05-29 | 1983-09-07 | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| CA000436233A CA1176573A (en) | 1980-05-29 | 1983-09-07 | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US154,581 | 1980-05-29 | ||
| US06/154,581 US4350156A (en) | 1980-05-29 | 1980-05-29 | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000436233A Division CA1176573A (en) | 1980-05-29 | 1983-09-07 | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1163517A true CA1163517A (en) | 1984-03-13 |
Family
ID=22551904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000377362A Expired CA1163517A (en) | 1980-05-29 | 1981-05-12 | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4350156A (enExample) |
| EP (1) | EP0041350B1 (enExample) |
| JP (1) | JPS5731869A (enExample) |
| BR (1) | BR8103271A (enExample) |
| CA (1) | CA1163517A (enExample) |
| DE (1) | DE3174039D1 (enExample) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4398906A (en) * | 1979-12-11 | 1983-08-16 | Frederic A. Bourke, Jr. | Method for externally treating the blood |
| US4612007A (en) * | 1981-06-16 | 1986-09-16 | Edelson Richard Leslie | Method and system for externally treating the blood |
| DE3147377A1 (de) * | 1981-11-30 | 1983-06-01 | Akzo Gmbh, 5600 Wuppertal | Verfahren und vorrichtung zur extrakorporalen entfernung von an eiweisskoerpern gebundenen toxinen |
| US4582598A (en) * | 1981-12-15 | 1986-04-15 | Baxter Travenol Laboratories, Inc. | Replacement fluid control system for a blood fractionation apparatus and the like |
| AU1045383A (en) * | 1981-12-15 | 1983-06-30 | Baxter Travenol Laboratories Inc. | Blood fractionation apparatus having fluid collection monitoring andfluid return control systems |
| US4634417A (en) * | 1982-12-06 | 1987-01-06 | Georgetown University | Process for treatment of tumors and apparatus therefor |
| US4684521A (en) * | 1982-12-08 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
| US4613322A (en) * | 1982-12-08 | 1986-09-23 | Edelson Richard Leslie | Method and system for externally treating the blood |
| DE3307830A1 (de) * | 1983-03-05 | 1984-09-06 | Hans Peter 5880 Lüdenscheid Berkenhoff | Verfahren und vorrichtung zur exkorporalen reinigung von blut |
| DE3310727A1 (de) * | 1983-03-24 | 1984-10-04 | B. Braun Melsungen Ag, 3508 Melsungen | Verfahren und vorrichtung zur selektiven, extrakorporalen abtrennung pathologischer und/oder toxischer blutbestandteile |
| US4683889A (en) * | 1983-03-29 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
| FR2548541B1 (fr) * | 1983-07-07 | 1986-09-12 | Rhone Poulenc Sa | Procede de plasmapherese et appareillage utilisable notamment pour ce procede |
| FR2548907B1 (fr) * | 1983-07-13 | 1985-11-08 | Rhone Poulenc Sa | Procede de plasmapherese et appareillage utilisable notamment pour ce procede |
| EP0156496B1 (en) * | 1984-02-24 | 1989-05-17 | Kuraray Co., Ltd. | Apparatus for the treatment of plasma |
| DE3422435A1 (de) * | 1984-06-16 | 1986-01-16 | B. Braun Melsungen Ag, 3508 Melsungen | Verfahren und vorrichtung zur selektiven abtrennung pathologischer und/oder toxischer spezies aus blut oder blutplasma unter verwendung von filterkerzen |
| US4663049A (en) * | 1984-07-05 | 1987-05-05 | University Of Utah | Process for therapeutic dissociation of immune complexes and removal of antigens |
| US4776964A (en) * | 1984-08-24 | 1988-10-11 | William F. McLaughlin | Closed hemapheresis system and method |
| US4708713A (en) * | 1984-11-16 | 1987-11-24 | Anisa Medical, Inc. | Method and system for removing immunosuppressive components from the blood of mammals |
| US4895558A (en) * | 1985-07-15 | 1990-01-23 | University Of Queensland | Autologous plasma delipidation using a continuous flow system |
| JPH0720986B2 (ja) * | 1985-10-07 | 1995-03-08 | 日本ケミカルリサ−チ株式会社 | 生理活性物質の製造法 |
| SE8605291L (sv) * | 1985-12-19 | 1987-06-20 | Cleveland Clinic Foundation | Termofiltrering av plasma |
| US4728430A (en) | 1986-02-10 | 1988-03-01 | Millipore Corporation | Diafiltration method |
| US4789482A (en) * | 1986-02-10 | 1988-12-06 | Millipore Corporation | Method for separating liquid compositions on the basis of molecular weight |
| NO160487C (no) * | 1986-11-26 | 1989-04-26 | Fasting Biotech As | Anordning for fjerning av kryoglobuliner. |
| US5053127A (en) * | 1987-01-13 | 1991-10-01 | William F. McLaughlin | Continuous centrifugation system and method for directly deriving intermediate density material from a suspension |
| US4944883A (en) * | 1987-01-13 | 1990-07-31 | Schoendorfer Donald W | Continuous centrifugation system and method for directly deriving intermediate density material from a suspension |
| US4883462A (en) * | 1987-01-30 | 1989-11-28 | Baxter Travenol Laboratories, Inc. | Blood extraction assist apparatus and method |
| NO874882L (no) * | 1987-11-24 | 1989-05-25 | Fasting Biotech As | Fremgangsmaate ved konsentrering av faktor viii. |
| US4851126A (en) * | 1987-11-25 | 1989-07-25 | Baxter International Inc. | Apparatus and methods for generating platelet concentrate |
| US5188588A (en) * | 1987-11-25 | 1993-02-23 | Baxter Internatonal Inc. | Single needle continuous hemapheresis apparatus and methods |
| US5484396A (en) * | 1988-11-17 | 1996-01-16 | Naficy; Sadeque S. | Method and device for treatment of HIV infections and AIDS |
| EP1327454A3 (en) * | 1989-08-02 | 2003-12-03 | Mitra Medical Technology AB | Method of treatment with medical agents |
| US5418130A (en) * | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
| US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| SE9100142L (sv) | 1991-01-17 | 1992-07-18 | Bengt Sandberg | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
| DE69212088T2 (de) * | 1991-03-26 | 1996-11-21 | Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima | Verfahren und vorrichtung zum filtern von plasma |
| US5217618A (en) * | 1991-08-26 | 1993-06-08 | Terumo Kabushiki Kaisha | Plasma purification treatment |
| US5549834A (en) * | 1991-12-23 | 1996-08-27 | Baxter International Inc. | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes |
| US5690835A (en) * | 1991-12-23 | 1997-11-25 | Baxter International Inc. | Systems and methods for on line collection of cellular blood components that assure donor comfort |
| US5330420A (en) * | 1992-01-13 | 1994-07-19 | Therakos, Inc. | Hemolysis detector |
| GB9218239D0 (en) * | 1992-08-27 | 1992-10-14 | Pall Corp | Processing of protein-containing body fluids |
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DK0710126T3 (da) | 1993-07-30 | 2004-08-09 | Aruba Internat Pty Ltd | Plasmadelipidationssystem |
| AU3815795A (en) * | 1994-11-09 | 1996-06-06 | Mitsubishi Rayon Company Limited | Hollow-filament plasma-filtering membrane and plasma-filtering module |
| AUPN030794A0 (en) | 1994-12-22 | 1995-01-27 | Aruba International Pty Ltd | Discontinuous plasma or serum delipidation |
| US5628727A (en) * | 1995-08-15 | 1997-05-13 | Hakky; Said I. | Extracorporeal virioncidal apparatus |
| GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
| PT938320E (pt) * | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
| US8043835B1 (en) | 1996-03-26 | 2011-10-25 | Oncomedx, Inc. | Methods for detecting and monitoring cancer using extracellular RNA |
| US6759217B2 (en) * | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US7785842B2 (en) * | 1996-03-26 | 2010-08-31 | Oncomedx, Inc. | Comparative analysis of extracellular RNA species |
| US20070009934A1 (en) * | 1997-03-14 | 2007-01-11 | Kopreski Michael S | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US8440396B2 (en) * | 1997-03-14 | 2013-05-14 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US20090233276A1 (en) * | 1998-09-22 | 2009-09-17 | Oncomedx, Inc. | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions |
| US8163524B2 (en) * | 1998-09-22 | 2012-04-24 | Oncomedx, Inc. | Comparative analysis of extracellular RNA species |
| US20060204989A1 (en) * | 1998-09-22 | 2006-09-14 | Kopreski Michael S | Comparative analysis of extracellular RNA species |
| EP1140252A2 (en) * | 1998-12-29 | 2001-10-10 | Occulogix Corporation | Rheological treatment methods and related apheresis systems |
| GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US6821968B2 (en) | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| US8535258B2 (en) * | 2000-03-24 | 2013-09-17 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| US6787040B2 (en) | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
| US8597516B2 (en) * | 2000-05-16 | 2013-12-03 | Immunocept, L.L.C. | Methods and systems for colloid exchange therapy |
| US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
| US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| US20090017069A1 (en) | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
| US7439052B2 (en) * | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
| US20060060520A1 (en) * | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US7033500B2 (en) * | 2001-06-25 | 2006-04-25 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| EP1409108A4 (en) * | 2001-06-25 | 2007-11-14 | Lipid Sciences Inc | HOLLOW FIBER CONTACTOR SYSTEMS FOR THE REMOVAL OF LIPIDS FROM LIQUIDS |
| AU2002345741B2 (en) * | 2001-06-25 | 2007-11-15 | Eli Lilly And Company | Systems and methods using a solvent for the removal of lipids from fluids |
| ES2367280T3 (es) * | 2001-07-25 | 2011-11-02 | Oncomedx Inc. | Métodos para evaluar estados patológicos usando arn extracelular. |
| WO2003015616A2 (en) * | 2001-08-17 | 2003-02-27 | Spencer Dudley W C | Hemodialysis assembly and method |
| US20100159464A1 (en) * | 2001-11-05 | 2010-06-24 | Oncomedx, Inc. | Method for Detection of DNA Methyltransferase RNA in Plasma and Serum |
| US20030104454A1 (en) * | 2001-11-05 | 2003-06-05 | Kopreski Michael S. | Method for detection of DNA methyltransferase RNA in plasma and serum |
| US6852231B2 (en) | 2002-02-15 | 2005-02-08 | Denco, Inc. | Spin-hemodialysis assembly and method |
| CN1674955A (zh) * | 2002-08-13 | 2005-09-28 | 阿尔比奥技术公司 | 选择性血浆交换治疗 |
| KR100459432B1 (ko) * | 2002-08-21 | 2004-12-03 | 엘지전자 주식회사 | 이동통신 시스템의 핸드오버 처리방법 |
| EP1534243A4 (en) * | 2002-08-26 | 2008-08-13 | Lipid Sciences Inc | TREATMENT OF ALZHEIMER WITH ENTLIPIDED PROTEIN PARTICLES |
| US20080160107A1 (en) * | 2002-09-10 | 2008-07-03 | Nitric Biotherapeutics, Inc. | Use of nitric oxide gas to treat blood and blood products |
| US7207964B2 (en) * | 2003-03-17 | 2007-04-24 | Hemavation, Llc | Apparatus and method for down-regulating immune system mediators in blood |
| US7169303B2 (en) * | 2003-05-28 | 2007-01-30 | Hemocleanse Technologies, Llc | Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems |
| DE10324668A1 (de) * | 2003-05-30 | 2004-12-23 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur extrakorporalen Bestrahlung einer Bilirubin enthaltenden Flüssigkeit und Verfahren hierfür |
| US7375191B2 (en) * | 2003-07-03 | 2008-05-20 | Lipid Science, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| US7393826B2 (en) * | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| US6960803B2 (en) * | 2003-10-23 | 2005-11-01 | Silicon Storage Technology, Inc. | Landing pad for use as a contact to a conductive spacer |
| US20050197496A1 (en) * | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
| CN2698358Y (zh) * | 2004-04-06 | 2005-05-11 | 上海江夏血液技术有限公司 | 血液过滤装置 |
| PT1949915E (pt) * | 2004-04-30 | 2012-11-27 | Biopheresis Technologies Inc | Método e sistema para remover rfnt1,rfnt2, e ril2 solúveis em pacientes |
| US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
| JP4899040B2 (ja) * | 2005-07-01 | 2012-03-21 | 国立大学法人 岡山大学 | ビリルビン変性器及びビリルビン透析装置 |
| US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
| WO2007049286A1 (en) * | 2005-10-27 | 2007-05-03 | Tata Memorial Centre | A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma |
| US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
| AT505433B1 (de) * | 2007-07-06 | 2009-10-15 | Technoclone Ges M B H | Plasmafiltration |
| US20090136942A1 (en) * | 2007-09-18 | 2009-05-28 | Oncomedx, Inc. | Analysis of Extracellular RNA |
| US8672869B2 (en) * | 2007-10-30 | 2014-03-18 | Bellco S.R.L. | Kit, system and method of treating myeloma patients |
| WO2009065082A1 (en) * | 2007-11-14 | 2009-05-22 | Pathway Medical Technologies, Inc. | Methods and systems for biological sample collection and analysis |
| WO2009094666A2 (en) * | 2008-01-25 | 2009-07-30 | Baylor College Of Medicine | Cryoaggregate filtration for the treatment of cardiomyopathy and other autoimmune diseases |
| US8202240B2 (en) * | 2008-08-12 | 2012-06-19 | Caridianbct, Inc. | System and method for collecting plasma protein fractions from separated blood components |
| US8123713B2 (en) * | 2008-08-12 | 2012-02-28 | Caridian Bct, Inc. | System and method for collecting plasma protein fractions from separated blood components |
| WO2011090943A1 (en) * | 2010-01-22 | 2011-07-28 | Baylor College Of Medicine | Removal of pathological albumin from a subject's plasma |
| US9694128B1 (en) * | 2010-02-24 | 2017-07-04 | Brian LeBerthon | Device and method for administering an anti-cancer substance |
| AU2013222414B2 (en) * | 2012-02-21 | 2018-02-15 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
| US10624924B2 (en) | 2012-03-12 | 2020-04-21 | Grifols, S.A. | Method and device for treating blood cholesterol disorders |
| US20160022895A1 (en) * | 2013-01-15 | 2016-01-28 | Takatori Corporation | Stock solution concentrating device, stock solution treatment device, and circulation-type treatment device |
| US9227005B2 (en) | 2013-03-14 | 2016-01-05 | Brian J LeBerthon | Method and device for treating cancer |
| CA2916566A1 (fr) | 2013-07-05 | 2015-01-08 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Matrice de chromatographie d'affinite |
| AU2015201496B2 (en) | 2014-06-03 | 2019-10-31 | Grifols Worldwide Operations Limited | Use of plasmapheresis to treat blood pressure disorders |
| WO2016104582A1 (ja) * | 2014-12-26 | 2016-06-30 | 旭化成メディカル株式会社 | 体腔液処理システム |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN118594035A (zh) | 2017-11-22 | 2024-09-06 | Hdl治疗公司 | 用于对血浆处理系统的流体回路进行灌注的系统和方法 |
| CA3087207A1 (en) | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579441A (en) * | 1968-04-19 | 1971-05-18 | Hydronautics | Blood purification by dual filtration |
| US3705100A (en) * | 1970-08-25 | 1972-12-05 | Amicon Corp | Blood fractionating process and apparatus for carrying out same |
| US3788319A (en) * | 1971-07-30 | 1974-01-29 | Univ Iowa State Res Found Inc | System for exchanging blood ultrafiltrate |
| US3802432A (en) * | 1972-05-18 | 1974-04-09 | I Djerassi | Apparatus for filtration-leukopheresis for separation and concentration of human granulocytes |
| US4006078A (en) * | 1974-07-08 | 1977-02-01 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of soluble edible protein from leafy green crops |
| US3941356A (en) * | 1974-11-13 | 1976-03-02 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Method and apparatus for continuous mixing of blood plasma and additives |
| GB1558370A (en) * | 1975-09-26 | 1979-12-28 | Asahi Chemical Ind | Blood treating apparatus |
| DE2553416A1 (de) * | 1975-11-27 | 1977-06-02 | Hager & Elsaesser | Verfahren zum abtrennen von geloesten stoffen aus einer loesung |
| US4103685A (en) * | 1976-01-05 | 1978-08-01 | Lupien Paul J | Method and apparatus for extravascular treatment of blood |
| JPS52155888A (en) * | 1976-06-22 | 1977-12-24 | Mitsui Toatsu Chemicals | Device for continuously removing material in blood flow |
| US4111199A (en) * | 1977-03-31 | 1978-09-05 | Isaac Djerassi | Method of collecting transfusable granulocytes by gravity leukopheresis |
| JPS5416896A (en) * | 1977-06-21 | 1979-02-07 | Asahi Medical Co | Blood dialyser |
| US4191182A (en) * | 1977-09-23 | 1980-03-04 | Hemotherapy Inc. | Method and apparatus for continuous plasmaphersis |
| US4223672A (en) * | 1979-02-08 | 1980-09-23 | Baxter Travenol Laboratories, Inc. | Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease |
| US4215688A (en) * | 1979-02-09 | 1980-08-05 | Baxter Travenol Laboratories, Inc. | Apparatus for the extracorporeal treatment of disease |
| US4350594A (en) * | 1980-04-16 | 1982-09-21 | Kuraray Co., Ltd. | Blood purification using plural ultrafiltration stages |
-
1980
- 1980-05-29 US US06/154,581 patent/US4350156A/en not_active Expired - Lifetime
-
1981
- 1981-05-12 CA CA000377362A patent/CA1163517A/en not_active Expired
- 1981-05-22 EP EP81302297A patent/EP0041350B1/en not_active Expired
- 1981-05-22 DE DE8181302297T patent/DE3174039D1/de not_active Expired
- 1981-05-26 BR BR8103271A patent/BR8103271A/pt unknown
- 1981-05-29 JP JP8371481A patent/JPS5731869A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0134626B2 (enExample) | 1989-07-20 |
| EP0041350A2 (en) | 1981-12-09 |
| BR8103271A (pt) | 1982-02-16 |
| EP0041350A3 (en) | 1982-02-17 |
| JPS5731869A (en) | 1982-02-20 |
| EP0041350B1 (en) | 1986-03-12 |
| DE3174039D1 (en) | 1986-04-17 |
| US4350156A (en) | 1982-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1163517A (en) | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid | |
| US4648974A (en) | Process for the selective extracorporeal separation of blood constituents | |
| Falkenhagen et al. | Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances | |
| JP5711330B2 (ja) | 一部が蛋白質に結合した物質を取除く装置 | |
| CA1142175A (en) | Fractionation of protein mixtures by salting out followed by dialysis treatment | |
| US4966709A (en) | Thermofiltration of plasma | |
| EP2771045B1 (en) | Method for the reduction or elimination of one or more components from a blood product | |
| EP0172018A2 (en) | Method and apparatus for treatment to remove immunoreactive substances from blood | |
| CA1086235A (en) | Continuous removing system of blood substances by extra corporeal circulation | |
| WO1979001121A1 (en) | Process for separating blood cell-containing liquid suspensions by filtration | |
| Agishi et al. | Double filtration plasmapheresis | |
| WO2015153287A1 (en) | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome | |
| US4968432A (en) | Treatment of liquid including blood components | |
| Nosé et al. | Clinical thermofiltration: initial application | |
| JP2002526172A (ja) | 生物学的流体フィルターおよびシステム | |
| US5217618A (en) | Plasma purification treatment | |
| Ronco et al. | Basic mechanisms and definitions for continuous renal replacement therapies | |
| JPS626693B2 (enExample) | ||
| Siami et al. | Current topics on cryofiltration technologies | |
| Malchesky et al. | Macromolecule removal from blood | |
| CA1176573A (en) | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid | |
| CA1176574A (en) | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid | |
| US5057226A (en) | Treatment of liquid including blood components | |
| Borberg | Problems of plasma exchange therapy | |
| EP0076320A1 (en) | Method and apparatus for treating blood and the like |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |